Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 77,862
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12564640 | Protein-antiviral compound conjugates | 🖼🧊📄§ | 2026-03-03 | 2043-07-24 | 0 | 31 |
| 12567155 | Systems and methods for platform agnostic whole body image segmentation | 🖼🧊📄§ | 2026-03-03 | 2044-10-31 | 0 | 31 |
| 12565680 | Cancer neoantigens and their utilities in cancer vaccines and TCR-based cancer immunotherapy | 🖼🧊📄§ | 2026-03-03 | 2039-04-25 | 0 | 31 |
| 12565520 | Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (LRRK2) | 🖼🧊📄§ | 2026-03-03 | 2041-02-25 | 0 | 31 |
| 12564559 | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | 🖼🧊📄§ | 2026-03-03 | 2042-05-04 | 0 | 31 |
| 12564562 | Injectable epinephrine formulations demonstrating stability over time | 🖼🧊📄§ | 2026-03-03 | 2042-10-28 | 0 | 31 |
| 12564648 | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors | 🖼🧊📄§ | 2026-03-03 | 2045-04-24 | 0 | 31 |
| 12564612 | Microbial strains and antibiotics | 🖼🧊📄§ | 2026-03-03 | 2041-08-18 | 0 | 31 |
| 12564590 | Combinations of menin inhibitors and CYP3A4 inhibitors and methods of use thereof | 🖼🧊📄§ | 2026-03-03 | 2041-04-07 | 0 | 31 |
| 12564622 | Preventing cytokine release syndrome | 🖼🧊📄§ | 2026-03-03 | 2042-12-09 | 0 | 31 |
| 12564608 | Use of ghost nanovesicles as therapeutics | 🖼🧊📄§ | 2026-03-03 | 2040-09-11 | 0 | 31 |
| 12564563 | Composition and methods for treating pathogenic infections on wounds | 🖼🧊📄§ | 2026-03-03 | 2040-12-22 | 0 | 31 |
| 12565467 | Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases | 🖼🧊📄§ | 2026-03-03 | 2043-12-12 | 0 | 31 |
| 12564580 | Mitochondria-targeted isoketal/isolevuglandin scavengers and uses thereof | 🖼🧊📄§ | 2026-03-03 | 2041-01-27 | 0 | 31 |
| 12564588 | HECT E3 ubiquitin liagase inhibitors and uses thereof | 🖼🧊📄§ | 2026-03-03 | 2042-01-21 | 0 | 31 |
| 12564567 | Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus | 🖼🧊📄§ | 2026-03-03 | 2043-11-27 | 0 | 31 |
| 12564600 | System for enhancing therapeutic compliance of the anti-cancer compound E7766 | 🖼🧊📄§ | 2026-03-03 | 2040-07-01 | 0 | 31 |
| 12564609 | Hematopoietic stem cell engraftment with a combination of agents | 🖼🧊📄§ | 2026-03-03 | 2041-10-14 | 0 | 31 |
| 12564628 | Epstein-BARR virus nucleic acid constructs and vaccines made therefrom, and methods of using same | 🖼🧊📄§ | 2026-03-03 | 2042-06-22 | 0 | 31 |
| 12564596 | Agents and methods for modulating pathogen activity | 🖼🧊📄§ | 2026-03-03 | 2039-09-30 | 0 | 31 |
| 12564581 | Pyrazole pharmaceutical composition | 🖼🧊📄§ | 2026-03-03 | 2040-12-18 | 0 | 31 |
| 12564642 | CEACAM5 antibody-drug conjugate formulation | 🖼🧊📄§ | 2026-03-03 | 2041-11-09 | 0 | 31 |
| 12564627 | System for producing and delivering contactless veterinary passive immunization | 🖼🧊📄§ | 2026-03-03 | 2045-05-09 | 0 | 31 |
| 12564561 | Dilute ready to use large volume containers of phenylephrine | 🖼🧊📄§ | 2026-03-03 | 2042-02-14 | 0 | 31 |
| 12565521 | Systems, kits, and methods for forming in situ silk fibroin fibers and/or aerosols | 🖼🧊📄§ | 2026-03-03 | 2043-11-03 | 0 | 31 |
| 12565535 | Chimeric antigen receptors targeted to PSCA | 🖼🧊📄§ | 2026-03-03 | 2042-08-17 | 0 | 31 |
| 12565682 | Methods of treating cancer | 🖼🧊📄§ | 2026-03-03 | 2040-11-25 | 0 | 31 |
| 12565650 | STAUFEN1 regulating agents and associated methods | 🖼🧊📄§ | 2026-03-03 | 2044-04-01 | 0 | 31 |
| 12565518 | Hybrid cyclic libraries and screens thereof | 🖼🧊📄§ | 2026-03-03 | 2044-02-07 | 0 | 31 |
| 12565529 | Methods for treating type 1 diabetes | 🖼🧊📄§ | 2026-03-03 | 2042-05-24 | 0 | 31 |
| 12565530 | Combination therapy with targeted 4-1BB (CD137) agonists/anti-FAP binding domain and anti-CEA/anti-CD3 bispecific antibody | 🖼🧊📄§ | 2026-03-03 | 2043-02-09 | 0 | 31 |
| 12565532 | Monoclonal antibodies that bind EGFRvIII and their use | 🖼🧊📄§ | 2026-03-03 | 2040-07-01 | 0 | 31 |
| 12565538 | FCRN/antigen-binding molecules and methods of use | 🖼🧊📄§ | 2026-03-03 | 2045-07-01 | 0 | 31 |
| 12565534 | Nano-antibody targeting CAIX antigen and application thereof | 🖼🧊📄§ | 2026-03-03 | 2040-08-25 | 0 | 31 |
| 12565537 | Compositions and methods targeting the nucleotide free state of RAS to block oncogenic signaling and transformation | 🖼🧊📄§ | 2026-03-03 | 2040-06-18 | 0 | 31 |
| 12564601 | Methods for treating hepatitis B infection | 🖼🧊📄§ | 2026-03-03 | 2042-02-02 | 0 | 31 |
| 12564829 | Biologically applicable water-soluble heterogeneous catalysts for para-hydrogen induced polarization | 🖼🧊📄§ | 2026-03-03 | 2042-03-14 | 0 | 31 |
| 12564592 | Injectable leucovorin formulations and methods of preparing same | 🖼🧊📄§ | 2026-03-03 | 2045-07-14 | 0 | 31 |
| 12565642 | Engineered DNASE enzymes for thrombosis therapy | 🖼🧊📄§ | 2026-03-03 | 2043-10-30 | 0 | 31 |
| 12564551 | Composition or oat extract comprising avenanthramide and β-glucan | 🖼🧊📄§ | 2026-03-03 | 2040-03-06 | 0 | 31 |
| 12564822 | Device for manufacture of T-cells for autologous cell therapy | 🖼🧊📄§ | 2026-03-03 | 2042-03-02 | 0 | 31 |
| 12564556 | Compositions comprising disodium levofolinate | 🖼🧊📄§ | 2026-03-03 | 2042-12-22 | 0 | 31 |
| 12564585 | Nutraceuticals having sustained release for improved bioavailability and method of production | 🖼🧊📄§ | 2026-03-03 | 2040-12-18 | 0 | 31 |
| 12564552 | Oral product with a basic amine and an ion pairing agent | 🖼🧊📄§ | 2026-03-03 | 2042-09-29 | 0 | 31 |
| 12564613 | Strains having effects of preventing or treating cancers | 🖼🧊📄§ | 2026-03-03 | 2039-05-08 | 0 | 31 |
| 12564575 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | 🖼🧊📄§ | 2026-03-03 | 2042-04-21 | 0 | 31 |
| 12564202 | Composition for alleviating, preventing or treating sarcopenia, containing whey protein hydrolysate as active ingredient | 🖼🧊📄§ | 2026-03-03 | 2040-09-25 | 0 | 31 |
| 12564634 | Highly dispersible zinc phthalocyanine-silica nanotubes and preparation method therefor | 🖼🧊📄§ | 2026-03-03 | 2040-06-02 | 0 | 31 |
| 12564635 | Long-lived gadolinium based tumor targeted imaging and therapy agents | 🖼🧊📄§ | 2026-03-03 | 2043-02-27 | 0 | 31 |
| 12564647 | Optimized expression cassettes for gene therapy | 🖼🧊📄§ | 2026-03-03 | 2042-07-08 | 0 | 31 |